Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
10:32am, Tuesday, 27'th Sep 2022
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Bristol Myers Sotyktu Approval Sends Ventyx Stock Soaring: Consider Buying Both
04:56pm, Friday, 23'rd Sep 2022
Big Pharma Bristol Myers Squibb won approval for plaque psoriasis therapy Sotyktu on September 9th - the drug may have $4bn peak sales potential. Ventyx has a drug with the same MoA entering a Phase 2
Why Bristol Myers Squibb Stock Bounced Higher Today
03:56pm, Thursday, 22'nd Sep 2022
The big pharma stock continues to trounce the major market indexes so far this year.
Final Trades: Salesforce, Cheniere, Bristol Myers & more
02:30pm, Thursday, 22'nd Sep 2022
The "Halftime Report" traders give their top picks to watch for the second half.
Bristol Myers (BMY) Skin Cancer Drug Gets EC's Approval
10:32am, Monday, 19'th Sep 2022
Bristol Myers (BMY) gets EC approval for the fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor Opdivo (nivolumab and novel LAG-3-blocking antibody relatlimab.
2 Biotech Stocks You Can Buy and Hold for the Next Decade
09:37am, Monday, 19'th Sep 2022
It's hard to imagine a world in which pharmaceutical spending doesn't increase year in and year out.
Calif. Pharmaceutical Companies AbbVie And Bristol Myers Lay Off 360—Here Are The Major U.S. Layoffs This Summer
01:13pm, Saturday, 17'th Sep 2022
Forbes is tracking the biggest layoffs in the U.S. this summer as companies react to fears of a looming recession.
3 Stocks to Buy and Hold Forever
06:14am, Saturday, 17'th Sep 2022
These businesses are built for the long run.
Bristol Myers' (BMY) Opdivo Meets Main Goal in Melanoma Study
03:48pm, Friday, 16'th Sep 2022
Bristol Myers' (BMY) immuno-oncology drug Opdivo demonstrates a statistically significant and clinically meaningful improvement in recurrence-Free survival (RFS) in patients with Stage IIB/C melanoma.
A 'Game-Changing' Tool In Prostate Cancer Stokes A Huge Gain For Lantheus Stock
08:00am, Friday, 16'th Sep 2022
Lantheus Holdings' Definity continues to grow. But its new Pylarify imaging tool underpins triple-digit gains for LNTH stock.
Consumer group says drugmakers abuse U.S. patent system to keep prices high
08:41pm, Thursday, 15'th Sep 2022
Makers of the top selling drugs in the United States are costing patients billions of dollars and worsening a drug pricing crisis by abusing the U.S. patent system to stifle competition and inflate pr
Why Bristol Myers Squibb Triumphed On Thursday
06:38pm, Thursday, 15'th Sep 2022
Investors were cheered by good news from the lab.
Is Most-Watched Stock Bristol Myers Squibb Company (BMY) Worth Betting on Now?
10:32am, Tuesday, 13'th Sep 2022
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
7 Screaming Buy Stock Picks to Beat the September Market Slump
06:30am, Tuesday, 13'th Sep 2022
Finding stock picks to beat the market are rare finds nowadays. In September stock markets began on downbeat momentum following the S&P 500 rally throughout the summer.
Bristol Myers (BMY) Gets FDA Approval for Psoriasis Candidate
05:18pm, Monday, 12'th Sep 2022
Bristol Myers (BMY) secures an FDA nod for Sotyktu to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
